beta-Eudesmol is a woody sesquiterpene alcohol found in several medicinal-plant and wood-oil profiles and already represented indirectly in the AromaForge archive through combined eudesmol peaks. The public evidence base is materially stronger here than for many minor sesquiterpenes: live source checks support its identity and multiple preclinical findings in angiogenesis, mast-cell, neuronal, and gastrointestinal models, plus one small human stress-response study. That said, most of the literature remains experimental rather than clinical, so archive copy should frame beta-eudesmol as an active research constituent rather than a validated medical ingredient.
Chemical identity and composition
NIST and PubChem identify beta-eudesmol as C15H26O. NIST lists CAS 473-15-4 and aliases including beta-eudesmol and beta-selinenol, while Good Scents describes it as a woody natural-substances-and-extractives material.
Aroma and practical use
- Use the recorded woody, green, clove-like, turpentine-like descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
A 2005 European Journal of Pharmacology study reported that beta-eudesmol inhibited endothelial-cell proliferation, migration, tube formation, and in vivo angiogenesis models, with ERK1/2 blockade proposed as part of the mechanism.
This is one of the strongest constituent-specific beta-eudesmol findings in the reviewed literature, but it remains preclinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2017 Clinical and Experimental Pharmacology and Physiology paper reported that beta-eudesmol reduced mast-cell degranulation markers in vitro and lowered allergic-reaction endpoints in mouse models.
The paper supports a constituent-level anti-allergic research signal, but the evidence is still laboratory and animal based rather than clinical.
This experimental finding does not establish benefit, dose or safety in people using this blend.
A 2018/2019 Nutrients crossover study in 50 healthy adults reported lower post-stressor salivary 3-methoxy-4-hydroxyphenylglycol after beta-eudesmol beverage ingestion versus placebo, with no related adverse events reported in the study abstract.
This is the clearest human study located in this pass, but it addresses an acute stress biomarker in healthy volunteers rather than a disease outcome.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
A 2012 Journal of Ethnopharmacology mouse study reported that isolated beta-eudesmol stimulated small-intestinal motility and countered dopamine- and 5-HT3-related slowing of gastrointestinal motility.
This supports GI-motility research relevance, but the findings come from mouse pharmacology rather than human digestive-use evidence.
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
This pass did not verify a constituent-specific IFRA dermal limit for isolated beta-eudesmol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
The strongest human paper found reported no adverse events related to the test beverage in that acute study, but that does not establish broad finished-product safety.
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
Because much of the direct literature is pharmacology-focused and uses purified material in cell or animal systems, archive copy should avoid implying therapeutic efficacy or routine wellness outcomes.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
LimoneneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vivo nonhuman · effect
No source citation attached.
Read Limonene report →gamma-TerpineneAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro mechanistic · antioxidant
No source citation attached.
Read gamma-Terpinene report →How the effects were investigated
ERK and CREB signaling interference in angiogenesis models
Mouse and endothelial-cell studies reported reduced growth-factor-driven angiogenic signaling with blockade of ERK1/2 and suppression of CREB activation.
This experimental finding does not establish benefit, dose or safety in people using this blend.
mast-cell degranulation suppression
In cell and rodent allergy models, beta-eudesmol reduced release of histamine-related mediators and lowered intracellular calcium in activated mast-cell systems.
This experimental finding does not establish benefit, dose or safety in people using this blend.
calcium- and MAPK-linked neuronal signaling
PC12-cell work linked beta-eudesmol to intracellular calcium changes, inositol phosphate accumulation, MAPK phosphorylation, and neurite outgrowth.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No strong constituent-specific dermatology, inhalation-tolerance, or long-term human safety dataset for isolated beta-eudesmol was verified in this pass.
- Most direct activity papers are preclinical and should not be translated into disease-treatment language.
- Archive use would benefit from a stronger public odor reference beyond database-style descriptions.
- 2026-07-13 verification pass: confirmed no individual IFRA Standard exists for beta-eudesmol (full-text keyword search of IFRA 51st Amendment for 'eudesmol', no match) and no Tisserand & Young Essential Oil Safety monograph or EU Cosmetics Regulation Annex III listing was located. The prior dermal_limit_pct (20%) and sensitizing (true) values had no supporting citation and are corrected to null/unknown rather than presented as sourced facts.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.